Work

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus

Year: 2016

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Clinical Therapeutics

DOI: 10.1016/j.clinthera.2015.12.020

Authors: Carol Addy, Daniel Tatosian, Xiaoli S. Glasgow, Isaias N. Gendrano, Eunkyung Kauh, Ashley Martucci, Amy O. Johnson-Levonas, Diana Selverian, Catherine Z. Matthews, Marie Gutierrez, John A. Wagner, S. Aubrey Stoch

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2269601075

FWCI: 1.842

Cites: 26

Cited by: 26

Related to: 10